


CLAIMS

1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

- 5 X is N or C-R⁵;
 L is selected from a covalent bond, $-(CH_2)_n-O-$, $-O-(CH_2)_p-$, and $-SO_2-$;
 n is an integer selected from 0, 1, 2 and 3;
 p is an integer selected from 1, 2 and 3;
 A is:
 10 (i) C₆₋₁₄-aryl substituted with R⁶, R⁷ and R⁸; or
 (ii) 5-14 membered heteroaryl substituted with R⁹, R¹⁰ and R¹¹; or
 B is a bridged bicyclic heterocycle;
 R¹ is hydrogen or C₁₋₆-alkyl;
 R² is hydrogen or C₁₋₆-alkyl;
 15 R³ is hydrogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, halogen or hydroxy;
 R⁴ is hydrogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, halogen or hydroxy;
 R⁵ is hydrogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, halogen or hydroxy; and
 R⁶, R⁷, R⁸, R⁹, R¹⁰, and R¹¹ are independently selected from hydrogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, halogen, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, SF₅, C₁₋₆-alkylsulfonyl, cyano, C₃₋₁₀-cycloalkyl, C₆₋₁₄-aryl, and 5-14 membered heteroaryl, wherein said C₃₋₁₀-cycloalkyl, C₆₋₁₄-aryl, and 5-14 membered heteroaryl are optionally substituted with 1-2 substituents selected from halogen, cyano, SF₅, C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, and halo-C₁₋₆-alkoxy.
 20
2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is hydrogen.
 25
3. The compound of formula (I) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R² is hydrogen.

- 64 -


4. The compound of formula (I) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R³ is hydrogen.
5. The compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R⁴ is hydrogen.
- 5 6. The compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R⁵ is hydrogen.
7. The compound of formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R⁶ is selected from hydrogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, and halogen.
- 10 8. The compound of formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R⁶ is selected from halo-C₁₋₆-alkyl and halogen.
9. The compound of formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R⁶ is selected from CF₃, chloro, and fluoro.
10. The compound of formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R⁷ is selected from hydrogen and halogen.
- 15 11. The compound of formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R⁷ is halogen.
12. The compound of formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R⁷ is fluoro or chloro.
- 20 13. The compound of formula (I) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R⁸ is hydrogen.
14. The compound of formula (I) according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R⁹ is selected from hydrogen, C₃₋₁₀-cycloalkyl, and C₆₋₁₄-aryl, wherein said C₆₋₁₄-aryl is substituted with 1-2 substituents selected from halogen and halo-C₁₋₆-alkyl.
- 25 15. The compound of formula (I) according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R¹⁰ is selected from hydrogen and halogen.

- 65 -

16. The compound of formula (I) according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R^{11} is hydrogen.
17. The compound of formula (I) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein X is $C-R^5$.
- 5 18. The compound of formula (I) according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein L is selected from $-(CH_2)_n-O-$ and $-O-(CH_2)_p-$.
19. The compound of formula (I) according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 0 and 1.
- 10 20. The compound of formula (I) according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein p is 1.
21. The compound of formula (I) according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein A is C_{6-14} -aryl substituted with R^6 , R^7 and R^8 .
- 15 22. The compound of formula (I) according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein A is phenyl substituted with R^6 , R^7 and R^8 .
23. The compound of formula (I) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein B is a 6-14 membered bridged bicyclic heterocycle comprising 1-3 heteroatoms selected from N, S, and O.
- 20 24. The compound of formula (I) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein B is a 6-9 membered bridged bicyclic heterocycle comprising 1-2 heteroatoms selected from N and O.
- 25 25. The compound of formula (I) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein B is a 6-8 membered bridged bicyclic heterocycle comprising 1 nitrogen atom.
26. The compound of formula (I) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein B is selected from 8-


- 66 -

azabicyclo[3.2.1]octan-8-yl **(a)**; 3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl **(b)**;
3-azabicyclo[3.1.0]hexan-3-yl **(c)**; and 2-azabicyclo[2.2.1]heptan-2-yl **(d)**:



wherein a wavy line indicates the point of attachment to the carbonyl bridge bridging B to the hexahydropyrido oxazinone core of formula (I).


27. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (II):



wherein:

- 10 X is N or CH₃;
L is selected from a covalent bond, $-(CH_2)_n-O-$, $-OCH_2-$, and $-SO_2-$;
n is an integer selected from 0 and 1;
A is:
(i) C₆₋₁₄-aryl substituted with R⁶ and R⁷; or
15 (ii) 5-14 membered heteroaryl substituted with R⁹ and R¹⁰; or
B is a 6-9 membered bridged bicyclic heterocycle comprising 1-2 heteroatoms selected from N and O;
R⁶ is selected from hydrogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, and halogen;
R⁷ is selected from hydrogen and halogen;
20 R⁹ is selected from hydrogen, C₃₋₁₀-cycloalkyl, and C₆₋₁₄-aryl, wherein said C₆₋₁₄-aryl is substituted with 1-2 substituents selected from halogen and halo-C₁₋₆-alkyl; and
R¹⁰ is selected from hydrogen and halogen.

28. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (III):




- 67 -

wherein:


- L is selected from $-(CH_2)_n-O-$ and $-OCH_2-$;
 n is an integer selected from 0 and 1;
 A is C₆₋₁₄-aryl substituted with R⁶ and R⁷;
 5 B is a 6-8 membered bridged bicyclic heterocycle comprising 1 nitrogen atom;
 R⁶ is selected from halo-C₁₋₆-alkyl and halogen; and
 R⁷ is halogen.

29. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (III):



wherein:

- L is selected from $-(CH_2)_n-O-$ and $-OCH_2-$;
 n is an integer selected from 0 and 1;
 A is phenyl substituted with R⁶ and R⁷;
 15 B is selected from 8-azabicyclo[3.2.1]octan-8-yl (**(a)**); 3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl (**(b)**); 3-azabicyclo[3.1.0]hexan-3-yl (**(c)**); and 2-azabicyclo[2.2.1]heptan-2-yl (**(d)**):



- 20 wherein a wavy line indicates the point of attachment to the carbonyl bridge bridging B to the hexahydropyrido oxazinone core of formula (I);

R⁶ is selected from CF₃, chloro, and fluoro; and
 R⁷ is fluoro or chloro.

30. The compound of formula (I) according to any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is selected
 25 from the compounds disclosed in Table 1.


- 68 -

31. The compound of formula (I) according to any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is selected from the group consisting of:


- (4aR,8aS)-6-[(1R,5S,6r)-6-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[5-(2-chloro-4-fluoro-phenoxy)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[rel-(1R,4R,5S)-5-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; and
- (4aR,8aS)-6-[(1S,5R)-3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-8-azabicyclo[3.2.1]octane-8-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one.

32. A process of manufacturing the compounds of formula (I) according to any one of claims 1 to 31, or pharmaceutically acceptable salts thereof, comprising:

- (a) reacting a first amine of formula **1**, wherein R^1 and R^2 are as described in any one of claims 1 to 31,



with a second amine **2**, wherein A, B, L, X, R^3 and R^4 are as described in any one of claims 1 to 31



in the presence of a base and a urea forming reagent, to form said compound of formula (I); and optionally

- (b) transforming said compound of formula (I) to a pharmaceutically acceptable salts thereof.

- 69 -

33. A compound of formula (I) according to any one of claims 1 to 31, when manufactured according to the process of claim 32.
34. A compound of formula (I) according to any one of claims 1 to 31 and 33 for use as therapeutically active substance.
- 5 35. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 31 and 33 and a therapeutically inert carrier.
36. The use of a compound of formula (I) according to any one of claims 1 to 31 and 33, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 35 for the treatment or prophylaxis of neuroinflammation, neurodegenerative
10 diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.
37. The use of a compound of formula (I) according to any one of claims 1 to 31 and 33, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 35 for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease,
15 Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
38. A compound of formula (I) according to any one of claims 1 to 31 and 33, or a
20 pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 35 for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.
39. A compound of formula (I) according to any one of claims 1 to 31 and 33, or a
25 pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 35 for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain
30 associated with irritable bowel syndrome and/or visceral pain in a mammal.

- 70 -

40. The use of a compound of formula (I) according to any one of claims 1 to 31 and 33, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.
- 5 41. The use of a compound of formula (I) according to any one of claims 1 to 31 and 33, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian
10 cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
42. A method for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, and/or inflammatory bowel disease in a mammal,
15 which method comprises administering an effective amount of a compound of formula (I) according to any one of claims 1 to 31 and 33, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 35 to the mammal.
43. A method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity,
20 stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain in a mammal, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain which method comprises administering an effective amount of a compound of formula (I)
25 according to any one of claims 1 to 31 and 33, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 35 to the mammal.
44. The invention as described hereinbefore.